PHREESIA INC

Company Overview

Phreesia (PHR) is a Healthcare company in the Health Information Services industry that provides SaaS-based patient intake, registration, payments, clinical assessments and patient engagement solutions to ambulatory and hospital clients, plus a point-of-care channel and network solutions for life sciences and advocacy customers. The business mixes subscription and services revenue with payment-processing fees and a growing “network solutions” direct-to-patient marketing/insights line; the company services ~4,300 clients (AHSCs) and reports material transaction volumes and patient payments. Recent filing highlights show strong revenue and cash‑flow improvement driven by client adds, cross‑sell, and network growth, plus active investment in R&D, security/compliance (HITRUST, PCI‑DSS, SOC 2) and M&A (AccessOne agreement).

Executive Compensation Practices

In the Healthcare sector and Health Information Services industry, executive pay typically combines base salary, annual cash incentives and long‑term equity (RSUs and performance stock units). For Phreesia specifically, compensation is likely tied to subscription growth, AHSC additions and revenue per AHSC, payment‑processing volume, network solutions revenue, and margin/Adjusted EBITDA targets — all metrics management cites as primary performance drivers. The 10‑K indicates use of PSUs with Monte Carlo TSR valuation models, so a portion of long‑term pay is explicitly market‑performance linked (TSR) while other awards or bonuses may be indexed to operational goals (revenue, free cash flow, client retention, and product adoption). Capitalization of internal‑use software, acquisition accounting and amortization can materially affect GAAP results and therefore may influence bonus calculations and the structure/timing of equity grants or retention awards for key R&D and integration personnel.

Insider Trading Considerations

Insider trading patterns at Phreesia will be influenced by scheduled vesting of RSUs/PSUs (notably TSR‑based PSUs), seasonality in payment volumes, and material corporate milestones (quarterly results, large life‑sciences campaigns, breaches, or M&A like the AccessOne deal). Regulatory and operational risks — HIPAA/HITECH, evolving state privacy laws (CCPA/CPRA), TCPA, payment network rules, and cybersecurity exposures — create potential for sudden, material disclosure events that can meaningfully move the stock, so watch for pre‑announcement insider sales or 10b5‑1 plans around reporting dates. Also monitor option exercises, large equity grants, and sales tied to vesting windows; management statements about covenant compliance, use of bridge financing, or changes in payment‑processing relationships can presage insider activity as executives manage dilution, liquidity needs, or retention incentives.